The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR

Misfolding accounts for the endoplasmic reticulum–associated degradation of mutant cystic fibrosis transmembrane conductance regulators (CFTRs), including deletion of Phe508 (ΔF508) in the nucleotide-binding domain 1 (NBD1). To study the role of Phe508, the de novo folding and stability of NBD1, NBD2 and CFTR were compared in conjunction with mutagenesis of Phe508. ΔF508 and amino acid replacements that prevented CFTR folding disrupted the NBD2 fold and its native interaction with NBD1. ΔF508 caused limited alteration in NBD1 conformation. Whereas nonpolar and some aliphatic residues were permissive, charged residues and glycine compromised the post-translational folding and stability of NBD2 and CFTR. The results suggest that hydrophobic side chain interactions of Phe508 are required for vectorial folding of NBD2 and the domain-domain assembly of CFTR, representing a combined co- and post-translational folding mechanism that may be used by other multidomain membrane proteins.

[1]  Douglas C. Rees,et al.  The E. coli BtuCD Structure: A Framework for ABC Transporter Architecture and Mechanism , 2002, Science.

[2]  F. Hartl,et al.  Co-translational domain folding as the structural basis for the rapid de novo folding of firefly luciferase , 1999, Nature Structural Biology.

[3]  Andreas Engel.  Faculty Opinions recommendation of The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. , 2002 .

[4]  M. Welsh,et al.  Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.

[5]  G. Lukács,et al.  Conformational and Temperature-sensitive Stability Defects of the ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator in Post-endoplasmic Reticulum Compartments* , 2001, The Journal of Biological Chemistry.

[6]  G. Lukács,et al.  C-terminal Truncations Destabilize the Cystic Fibrosis Transmembrane Conductance Regulator without Impairing Its Biogenesis , 1999, The Journal of Biological Chemistry.

[7]  I. Braakman,et al.  Coordinated Nonvectorial Folding in a Newly Synthesized Multidomain Protein , 2002, Science.

[8]  J. Riordan,et al.  Differential Interactions of Nucleotides at the Two Nucleotide Binding Domains of the Cystic Fibrosis Transmembrane Conductance Regulator* , 2001, The Journal of Biological Chemistry.

[9]  R. Frizzell,et al.  The role of regulated CFTR trafficking in epithelial secretion. , 2003, American journal of physiology. Cell physiology.

[10]  J. Wine,et al.  Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*) , 1996, The Journal of Biological Chemistry.

[11]  J. M. Sauder,et al.  Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.

[12]  E. Schneider,et al.  Nucleotide-induced conformational changes of MalK, a bacterial ATP binding cassette transporter protein. , 1994, The Journal of biological chemistry.

[13]  Charles R Sanders,et al.  Disease-related misassembly of membrane proteins. , 2004, Annual review of biophysics and biomolecular structure.

[14]  J. Riordan,et al.  The First Nucleotide Binding Domain of Cystic Fibrosis Transmembrane Conductance Regulator Is a Site of Stable Nucleotide Interaction, whereas the Second Is a Site of Rapid Turnover* , 2002, The Journal of Biological Chemistry.

[15]  G. Lukács,et al.  Limited proteolysis as a probe for arrested conformational maturation of ΔF508 CFTR , 1998, Nature Structural Biology.

[16]  F. Hartl,et al.  Recombination of protein domains facilitated by co-translational folding in eukaryotes , 1997, Nature.

[17]  L. Limbird,et al.  The role of a conserved inter-transmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cell-surface turnover. , 2001, Molecular pharmacology.

[18]  Chad A Brautigam,et al.  Side chain and backbone contributions of Phe508 to CFTR folding , 2005, Nature Structural &Molecular Biology.

[19]  K D Wittrup,et al.  Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control* , 1998, The Journal of Biological Chemistry.

[20]  P. Pedersen,et al.  The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. , 1992, The Journal of biological chemistry.

[21]  A. Nairn,et al.  Severed Molecules Functionally Define the Boundaries of the Cystic Fibrosis Transmembrane Conductance Regulator's Nh2-Terminal Nucleotide Binding Domain , 2000, The Journal of general physiology.

[22]  B. Papsin,et al.  Misfolding diverts CFTR from recycling to degradation , 2004, The Journal of cell biology.

[23]  G. Heda,et al.  The ΔF508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells , 2001 .

[24]  J. M. Sauder,et al.  Structure of nucleotide‐binding domain 1 of the cystic fibrosis transmembrane conductance regulator , 2004, The EMBO journal.

[25]  R. Doolittle.  The multiplicity of domains in proteins. , 1995, Annual review of biochemistry.

[26]  C. Sanders,et al.  Destabilizing mutations promote membrane protein misfolding. , 2004, Biochemistry.

[27]  S. Dhani,et al.  Stable dimeric assembly of the second membrane-spanning domain of CFTR (cystic fibrosis transmembrane conductance regulator) reconstitutes a chloride-selective pore. , 2003, The Biochemical journal.

[28]  P. Pedersen,et al.  Cystic fibrosis transmembrane conductance regulator: solution structures of peptides based on the Phe508 region, the most common site of disease-causing DeltaF508 mutation. , 1999, Biochemistry.

[29]  D. Clarke,et al.  The ΔF508 Mutation Disrupts Packing of the Transmembrane Segments of the Cystic Fibrosis Transmembrane Conductance Regulator* , 2004, Journal of Biological Chemistry.

[30]  J. Brodsky.  Chaperoning the maturation of the cystic fibrosis transmembrane conductance regulator. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[31]  M. Welsh,et al.  The amino-terminal portion of CFTR forms a regulated CI− channel , 1994, Cell.

[32]  Wei Chen,et al.  Co-translational folding of an alphavirus capsid protein in the cytosol of living cells , 1999, Nature Cell Biology.

[33]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[34]  F. Hartl,et al.  Principles of Chaperone-Assisted Protein Folding: Differences Between in Vitro and in Vivo Mechanisms , 1996, Science.

[35]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[36]  Satoshi Omura,et al.  Degradation of CFTR by the ubiquitin-proteasome pathway , 1995, Cell.

[37]  G. Tusnády,et al.  Membrane Topology and Glycosylation of the Human Multidrug Resistance-associated Protein (*) , 1996, The Journal of Biological Chemistry.

[38]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[39]  P. Thomas,et al.  Alteration of the Cystic Fibrosis Transmembrane Conductance Regulator Folding Pathway , 1996, The Journal of Biological Chemistry.

[40]  R. Kopito,et al.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. , 2002, The Journal of clinical investigation.

[41]  J. Marshall,et al.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.

[42]  J. Riordan,et al.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.

[43]  J. Riordan,et al.  Characterization of polyclonal and monoclonal antibodies to cystic fibrosis transmembrane conductance regulator. , 1998, Methods in enzymology.

[44]  G. Lukács,et al.  Cooh-Terminal Truncations Promote Proteasome-Dependent Degradation of Mature Cystic Fibrosis Transmembrane Conductance Regulator from Post-Golgi Compartments , 2001, The Journal of cell biology.

[45]  M. Evans,et al.  Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene , 2002, Journal of Molecular Medicine.

[46]  Geoffrey Chang,et al.  Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. , 2003, Journal of molecular biology.

[47]  R. Kopito,et al.  Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. , 1994, The Journal of biological chemistry.

[48]  M. Welsh,et al.  Association of domains within the cystic fibrosis transmembrane conductance regulator. , 1997, Biochemistry.

[49]  P. Pedersen,et al.  Defective protein folding as a basis of human disease. , 1995, Trends in biochemical sciences.

[50]  A. D. Robertson,et al.  A functional R domain from cystic fibrosis transmembrane conductance regulator is predominantly unstructured in solution. , 2000, Proceedings of the National Academy of Sciences of the United States of America.